Phase III Miss In Glioblastoma Burdens VBL's Ovarian Cancer Trial
Executive Summary
It's bad news for Israel's VBL as the company's lead gene-based biologic has failed in a critical Phase III trial in brain cancer – the pressure is on now for success with this drug candidate in ovarian cancer.
You may also be interested in...
BMS’s Opdivo Misses Again In Glioblastoma Phase III Trial
A second failure for BMS’s Opdivo in brain cancer leaves it with just one final chance in newly diagnosed disease, where the bar is lower.
VC View: Deal-Making During A Pandemic And 2021 Expectations
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Snapshot: August Highlights
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Need a specific report? 1000+ reports available
Buy Reports